Checkpoint inhibitors function by blocking the inhibitory receptors like CTLA‐4 and PD‐1, which typically restrict the activity of T cells.[124] This action eliminates suppression, allowing existing tumor‐specific T cells to proliferate, act as effector cells, and fight against cancer cells. This evidence concerns the gene PDCD1 and neoplasm.